TNF-α-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species

Leukemia

Volumn 24, Issue 1, 2010, Pages 51-57

  Vahdat, A M ^a   Reiners, K S ^a   Simhadri, V L ^a   Eichenauer, D A ^a   Boll B ^a   Chalaris, A ^b   Simhadri, V R ^a   Wiegmann, K ^c   Krell, H W ^d   Rose John, S ^b   Engert, A ^a   Von Strandmann, E P ^a   Hansen, H P ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

ADAM17; Bortezomib; Human; Immunotherapy; Interleukin 6 receptor; Proteasome inhibition

Indexed keywords

ACETYLCYSTEINE; BORTEZOMIB; CASPASE INHIBITOR; CD30 ANTIGEN; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MDX 060; PROTEASOME INHIBITOR; REACTIVE OXYGEN METABOLITE; SYNDECAN 1; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DRUG POTENTIATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LEUKEMIA CELL LINE; LYMPHOMA CELL; LYMPHOMA CELL LINE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 74249090820     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.230     Document Type: Article

References (28)

1. Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007; 25: 2764-2769.
2. Bartlett NL, Younes A, Carabasi MH, Forero A, Rosenblatt JD, Leonard JP et al. A phase 1 multidose study of SGN-30 immuno-therapy in patients with refractory or recurrent CD30+ hemato-logic malignancies. Blood 2008; 111: 1848-1854.
3. Schnell R, Staak O, Borchmann P, Schwartz C, Matthey B, Hansen H et al. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res 2002; 8: 1779-1786.
4. Hansen HP, Dietrich S, Kisseleva T, Mokros T, Mentlein R, Lange HH et al. CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-alpha-converting enzyme. J Immunol 2000; 165: 6703-6709.
5. Saitoh Y, Yamamoto N, Dewan MZ, Sugimoto H, Martinez Bruyn VJ, Iwasaki Y et al. Overexpressed NF-kappaB-inducing kinase contributes to the tumorigenesis of adult T-cell leukemia and Hodgkin Reed-Sternberg cells. Blood 2008; 111: 5118-5129.
6. Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007; 109: 2700-2707.
7. Roccaro AM, Vacca A, Ribatti D. Bortezomib in the treatment of cancer. Recent Patents Anticancer Drug Discov 2006; 1: 397-403.
8. Boll B, Hansen H, Heuck F, Reiners K, Borchmann P, Rothe A et al. The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis. Blood 2005; 106: 1839-1842.
9. Peiretti F, Canault M, Bernot D, Bonardo B, Deprez-Beauclair P, Juhan-Vague I et al. Proteasome inhibition activates the transport and the ectodomain shedding of TNF-alpha receptors in human endothelial cells. J Cell Sci 2005; 118: 1061-1070.
10. Levine SJ, Adamik B, Hawari FI, Islam A, Yu ZX, Liao DW et al. Proteasome inhibition induces TNFR1 shedding from human airway epithelial (NCI-H292) cells. Am J Physiol Lung Cell Mol Physiol 2005; 289: L233-L243.
11. Reddy P, Slack JL, Davis R, Cerretti DP, Kozlosky CJ, Blanton RA et al. Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem 2000; 275: 14608-14614.
12. Horn-Lohrens O, Tiemann M, Lange H, Kobarg J, Hafner M, Hansen H et al. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). Int J Cancer 1995; 60: 539-544.
13. Beck G, Bottomley G, Bradshaw D, Brewster M, Broadhurst M, Devos R et al. (E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-bute-nyl]-20-isobutyl-20- (methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase. J Pharmacol Exp Ther 2002; 302: 390-396.
14. von Tresckow B, Kallen KJ, von Strandmann EP, Borchmann P, Lange H, Engert A et al. Depletion of cellular cholesterol and lipid rafts increases shedding of CD30. J Immunol 2004; 172: 4324-4331.
15. Blum KA, Johnson JL, Niedzwiecki D, Canellos GP, Cheson BD, Bartlett NL. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Leuk Lymphoma 2007; 48: 1313-1319.
16. Mendler JH, Kelly J, Voci S, Marquis D, Rich L, Rossi RM et al. Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. Ann Oncol 2008; 19: 1759-1764.
17. Trelle S, Sezer O, Naumann R, Rummel M, Keller U, Engert A et al. Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018). Haematologica 2007; 92: 568-569.
18. Eichenauer DA, Simhadri VL, EP von Strandmann, Ludwig A, Matthews V, Reiners KS et al. ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro. Cancer Res 2007; 67: 332-338.
19. von Strandmann EP, Hansen HP, Reiners KS, Schnell R, Borchmann P, Merkert S et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 2006; 107: 1955-1962.
20. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 54: 2817-2829.
21. Feng R, Oton A, Mapara MY, Anderson G, Belani C, Lentzsch S. The histone deacetylase inhibitor, PXD101, potentiates bortezo-mib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br J Haematol 2007; 139: 385-397.
22. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006; 107: 257-264.
23. Zhang Z, Oliver P, Lancaster JJ, Schwarzenberger PO, Joshi MS, Cork J et al. Reactive oxygen species mediate tumor necrosis factor alpha-converting, enzyme-dependent ectodomain shedding induced by phorbol myristate acetate. FASEB J 2001; 15: 303-305.
24. Sanderson MP, Abbott CA, Tada H, Seno M, Dempsey PJ, Dunbar AJ. Hydrogen peroxide and endothelin-1 are novel activators of betacellulin ectodomain shedding. J Cell Biochem 2006; 99: 609-623.
25. Chalaris A, Rabe B, Paliga K, Lange H, Laskay T, Fielding CA et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood 2007; 110: 1748-1755.
26. Borchmann P, Treml JF, Hansen HP, Gottstein C, Schnell R, Staak O et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood 2003; 102: 3737-3742.
27. Pruessmeyer J, Ludwig A. The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer. Semin Cell Dev Biol 2009; 20: 164-174.
28. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006; 80: 227-236.